



Contacts:

Susan M. Kanaya
Senior Vice President, Finance and Chief
Financial Officer or

Markus J. Cappel, Ph.D.
Senior Vice President, Corporate and
Business Development

650-210-2900
investor@chemocentryx.com

For media inquiries:

BCC Partners
Karen L. Bergman
650-575-1509
Michelle Corral
415-794-8662

For Immediate Release

ChemoCentryx Appoints Juan Jaen, Ph.D., Senior Vice President, Drug Discovery

Mountain View, CA – January 4, 2007 – ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced the appointment of Juan Jaen, Ph.D., to the position of Senior Vice President, Drug Discovery.

Dr. Jaen brings more than 20 years of expertise in drug discovery, chemistry and preclinical development across a number of therapeutic areas to ChemoCentryx. Dr. Jaen will be responsible for all of ChemoCentryx's drug discovery efforts, ranging from early research through preclinical development. He will report directly to Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer. Dr. Jaen's appointment coincides with the retirement of J.J. Kim Wright, Ph.D., who has served as ChemoCentryx's Senior Vice President, Medicinal Chemistry and Preclinical Development, since 2001. Dr. Wright will continue to consult to the company.

"It has been an honor and a privilege to have had the opportunity to work with someone of Kim's talent, and we very much appreciate his efforts in building a top-notch medicinal chemistry program at ChemoCentryx during his six-year tenure. While he will be universally missed by the team, we are pleased to welcome Juan to ChemoCentryx. Juan's track record of efficiently moving quality candidates into the clinic across a wide range of therapeutic areas, including inflammatory diseases and oncology, complements our own approach to drug discovery and development," said Dr. Schall. "We look forward to his valued contributions as we prepare to

advance a number of promising preclinical candidates into the clinic and continue to leverage our internal drug discovery expertise to further fuel our pipeline.”

Dr. Jaen joins ChemoCentryx after ten years at Tularik and then Amgen (following Tularik’s acquisition by Amgen in 2004), most recently serving as Vice President of Chemistry. During his tenure there, Dr. Jaen was instrumental in building a highly efficient drug discovery organization that delivered eight small molecule candidates into clinical development. In addition to his leadership role in shaping Tularik’s research portfolio, Dr. Jaen was responsible for various aspects of the company’s preclinical and clinical development projects and led a number of Tularik’s multiple corporate research collaborations. Prior to Tularik, Dr. Jaen spent 13 years at Parke-Davis/Warner-Lambert, most recently Chemistry Director, with responsibility for the neurodegenerative disease research area. Dr. Jaen holds a Ph.D. degree in Organic Chemistry from the University of Michigan. He is an author on more than 60 scientific publications and is an inventor on 39 issued U.S. patents.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a complex network of chemokine molecules, or ligands, and receptors that regulates inflammation. Based on their proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx’s lead compound, Traficet-EN®, a specific CCR9 antagonist, is currently in a multinational clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn’s disease. In August 2006, ChemoCentryx and GlaxoSmithKline entered into a worldwide strategic alliance to discover, develop and commercialize up to six novel medicines targeting four chemokine and chemoattractant receptors for a variety of inflammatory disorders. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the timing, success and cost of preclinical research and clinical studies, (ii) the timing, acceptability and review periods for regulatory filings, (iii) the availability of corporate partners, (iv) uncertainties relating to patent protection and intellectual property rights of third parties, (v) the impact of competitive products and technological changes, (vi) the availability of capital and the cost of capital, (vii) other vagaries in the biotechnology industry and (viii) other risks. ChemoCentryx undertakes no obligation to update or revise any forward-looking statements.

#